Login
$VRCA
$3.20 -$0.36 (10.11%) Live

$VRCA 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

– Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million –

06 Aug 2026 8-K: Results of Operations and Financial Condition

– Company reports record demand for YCANTH® as dispensed applicator units grew to 19,626 in

09 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

(a) Successor to and Continuation of Prior Plan. The Plan was originally adopted by the Board on May 30, 2018, approved by the Company’s stockholders on June 1, 2018 and initially became effective as of the IPO Date. The Plan is intended...

12 May 2026 8-K: Results of Operations and Financial Condition

– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed applicator units since launch –

11 Mar 2026 8-K: Results of Operations and Financial Condition

– YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 –

30 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

24 Nov 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 23, 2025, by and among Verrica Pharmaceuticals Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agre...

14 Nov 2025 8-K: Results of Operations and Financial Condition

– Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH®

12 Aug 2025 8-K: Results of Operations and Financial Condition; Other Events

– Company reports $12.7 million in revenue in Q2’25, consisting primarily of $4.5 million in YCANTH® revenue, net, reflecting sequential growth of 32.5% over Q1’25 and $8.0 million in milestone revenue from Torii Pharmaceutical –

30 Jul 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed, on January 24, 2025, The Nasdaq Stock Market LLC (“Nasdaq”) notified Verrica Pharmaceuticals Inc. (the “Company”) that, based upon the preceding 30-business day period, the Company no longer satisfied Nasdaq List...

23 Jul 2025 8-K: Material Modification to Rights of Security Holders

(Pursuant to Section 242 of the General Corporation Law of the State of Delaware)

01 Jul 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

12 Jun 2025 8-K: Entry into a Material Definitive Agreement

On June 10, 2025, Verrica Pharmaceuticals Inc. (the “Company”) entered into the sixth amendment and waiver (the “Sixth Amendment”) to its Credit Agreement dated as of July 26, 2023 (as amended prior to the Sixth Amendment, the “Credit Ag...

05 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 5, 2025, Verrica Pharmaceuticals Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered four proposals, each of which is described in more detail in the Company’s def...

13 May 2025 8-K: Results of Operations and Financial Condition

– Company reports $3.4 million in YCANTH revenue, reflective of increasing demand,

25 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

This Release Agreement (“Release” or “Agreement”) is made by and between Christopher G. Hayes (“you”) and Verrica Pharmaceuticals Inc. (the “Company”). A copy of this Release is an attachment to the Employment Agreement between the Compa...

02 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

11 Mar 2025 8-K: Results of Operations and Financial Condition

– Company generated quarterly sequential growth in YCANTH® dispensed applicator units of 12.3% in Q4’24 concurrent with significantly lower operating expenses –

21 Feb 2025 8-K: Entry into a Material Definitive Agreement

On February 18, 2025, Verrica Pharmaceuticals Inc. (the “Company”) entered into a waiver (the “Waiver”) to its Credit Agreement dated as of July 26, 2023 (as amended prior to the Waiver, the “Credit Agreement”), by and between the Compan...

30 Jan 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On January 24, 2025, Verrica Pharmaceuticals, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support